Jay Steingrub to Drug Administration Schedule
This is a "connection" page, showing publications Jay Steingrub has written about Drug Administration Schedule.
Connection Strength
0.076
-
Self WH, Semler MW, Bellomo R, Brown SM, deBoisblanc BP, Exline MC, Ginde AA, Grissom CK, Janz DR, Jones AE, Liu KD, Macdonald SPJ, Miller CD, Park PK, Reineck LA, Rice TW, Steingrub JS, Talmor D, Yealy DM, Douglas IS, Shapiro NI. Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a?Randomized Trial. Ann Emerg Med. 2018 10; 72(4):457-466.
Score: 0.036
-
Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Schoenfeld D, Steingrub J, Thompson BT. Randomized, placebo-controlled clinical trial of an aerosolized ?2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011 Sep 01; 184(5):561-8.
Score: 0.023
-
L?pez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004 Jan; 32(1):21-30.
Score: 0.013
-
Braden GL, Steingrub JS, Teres D. Treatment of hypophosphatemia. Crit Care Med. 1985 Nov; 13(11):995.
Score: 0.004